Related Experiment Video

Updated: Jan 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.7K

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

Maryam Nakhjavani1,2, Jennifer E Hardingham1,2, Helen M Palethorpe1,2

  • 1Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, Australia.

Journal of Breast Cancer
|October 11, 2019
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks targeted therapies, driving research into new molecular targets. This review summarizes current TNBC targets and drugs in clinical trials for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) is the most common breast cancer subtype in women globally.
  • TNBC is defined by the absence of estrogen, progesterone, and HER2 receptors, limiting targeted therapy options.
  • Patients with TNBC often face a poorer prognosis compared to other breast cancer subtypes.

Purpose of the Study:

  • To review and summarize molecular targets for TNBC.
  • To categorize identified targets into immune, intra-nuclear, intracellular, and cell surface categories.
  • To provide a comprehensive overview of current and potential TNBC therapeutic targets.

Main Methods:

  • Literature review focusing on molecular targets in TNBC.
  • Categorization of targets based on their cellular location or function.
  • Inclusion of drugs currently in Phase II or III clinical trials.

Main Results:

  • Identified and categorized various molecular targets within the immune system (e.g., immune checkpoint modulators), intracellularly, intra-nuclearly, and on the cell surface.
  • Summarized drugs under investigation for TNBC in ongoing clinical trials.
  • Highlighted potential novel targets for future drug development.

Conclusions:

  • Effective targeted therapies for TNBC are urgently needed due to its aggressive nature and limited treatment options.
  • The identified molecular targets represent promising avenues for developing novel TNBC therapies.
  • This review offers valuable insights for researchers seeking to advance TNBC treatment strategies.
Keywords:
Clinical trialDrug therapyTriple negative breast neoplasms

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

856
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K